X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

APTX

Closed

Aptinyx Inc

0.096
+0.003 (+3.22%)
Last Update: 29 Dec 2023 23:59:00
Yesterday: 0.0931
Day's Range: 0. - 0.
Send
When Written:
 
0.1248
Aptinyx Inc is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of novel therapies for the treatment of brain and nervous system disorders. The company was founded in 2015 and is headquartered in Evanston, Illinois.

Aptinyx's lead product candidate, NYX-2925, is a novel NMDA receptor modulator that is being developed for the treatment of chronic pain and other neurological disorders. The company is also developing a pipeline of other NMDA receptor modulators for the treatment of various CNS disorders, including depression, neuropathic pain, and cognitive impairment associated with schizophrenia.

Aptinyx is a publicly traded company listed on the Nasdaq stock exchange under the ticker symbol APTX. The company has partnerships with several pharmaceutical companies, including Allergan, Janssen, and Astellas Pharma, to develop and commercialize its products.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.209
X